Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 516

1.

Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor.

Kobie JJ, Zheng B, Bryk P, Barnes M, Ritchlin CT, Tabechian DA, Anandarajah AP, Looney RJ, Thiele RG, Anolik JH, Coca A, Wei C, Rosenberg AF, Feng C, Treanor JJ, Lee FE, Sanz I.

Arthritis Res Ther. 2011;13(6):R209. doi: 10.1186/ar3542. Epub 2011 Dec 16.

2.

The effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccination.

Gelinck LB, van der Bijl AE, Beyer WE, Visser LG, Huizinga TW, van Hogezand RA, Rimmelzwaan GF, Kroon FP.

Ann Rheum Dis. 2008 May;67(5):713-6. Epub 2007 Oct 26.

PMID:
17965123
3.

Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab.

van Assen S, Holvast A, Benne CA, Posthumus MD, van Leeuwen MA, Voskuyl AE, Blom M, Risselada AP, de Haan A, Westra J, Kallenberg CG, Bijl M.

Arthritis Rheum. 2010 Jan;62(1):75-81. doi: 10.1002/art.25033.

4.

Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients.

Kapetanovic MC, Saxne T, Nilsson JA, Geborek P.

Rheumatology (Oxford). 2007 Apr;46(4):608-11. Epub 2006 Nov 18.

PMID:
17114801
5.

Influenza vaccine administration in rheumatoid arthritis patients under treatment with TNFalpha blockers: safety and immunogenicity.

Salemi S, Picchianti-Diamanti A, Germano V, Donatelli I, Di Martino A, Facchini M, Nisini R, Biselli R, Ferlito C, Podestà E, Cappella A, Milanetti F, Rossi F, Amodeo R, Tabacco F, Di Rosa R, Laganà B, D Amelio R.

Clin Immunol. 2010 Feb;134(2):113-20. doi: 10.1016/j.clim.2009.09.014. Epub 2009 Oct 21.

PMID:
19846344
6.

TNF blockers show distinct patterns of immune response to the pandemic influenza A H1N1 vaccine in inflammatory arthritis patients.

França IL, Ribeiro AC, Aikawa NE, Saad CG, Moraes JC, Goldstein-Schainberg C, Laurindo IM, Precioso AR, Ishida MA, Sartori AM, Silva CA, Bonfa E.

Rheumatology (Oxford). 2012 Nov;51(11):2091-8. doi: 10.1093/rheumatology/kes202. Epub 2012 Aug 20.

PMID:
22908326
7.

Rituximab impairs immunoglobulin (Ig)M and IgG (subclass) responses after influenza vaccination in rheumatoid arthritis patients.

Westra J, van Assen S, Wilting KR, Land J, Horst G, de Haan A, Bijl M.

Clin Exp Immunol. 2014 Oct;178(1):40-7. doi: 10.1111/cei.12390.

8.

Impact of anti-rheumatic treatment on immunogenicity of pandemic H1N1 influenza vaccine in patients with arthritis.

Kapetanovic MC, Kristensen LE, Saxne T, Aktas T, Mörner A, Geborek P.

Arthritis Res Ther. 2014 Jan 2;16(1):R2. doi: 10.1186/ar4427.

9.

The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis.

Elkayam O, Caspi D, Reitblatt T, Charboneau D, Rubins JB.

Semin Arthritis Rheum. 2004 Feb;33(4):283-8.

PMID:
14978666
10.

Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.

Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, Zink A.

JAMA. 2009 Feb 18;301(7):737-44. doi: 10.1001/jama.2009.146.

PMID:
19224750
11.

The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab.

Arad U, Tzadok S, Amir S, Mandelboim M, Mendelson E, Wigler I, Sarbagil-Maman H, Paran D, Caspi D, Elkayam O.

Vaccine. 2011 Feb 11;29(8):1643-8. doi: 10.1016/j.vaccine.2010.12.072. Epub 2011 Jan 4.

PMID:
21211590
12.
13.

Lipid profile of rheumatoid arthritis patients treated with anti-tumor necrosis factor-alpha drugs changes according to disease activity and predicts clinical response.

Cacciapaglia F, Anelli MG, Rinaldi A, Serafino L, Covelli M, Scioscia C, Iannone F, Lapadula G.

Drug Dev Res. 2014 Nov;75 Suppl 1:S77-80. doi: 10.1002/ddr.21203.

PMID:
25381986
14.

Serum levels of lipoprotein(a) and E-selectin are reduced in rheumatoid arthritis patients treated with methotrexate or methotrexate in combination with TNF-α-inhibitor.

Hjeltnes G, Hollan I, Førre O, Wiik A, Lyberg T, Mikkelsen K, Agewall S.

Clin Exp Rheumatol. 2013 May-Jun;31(3):415-21. Epub 2013 Mar 4.

PMID:
23465067
15.

The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis.

Elkayam O, Bashkin A, Mandelboim M, Litinsky I, Comaheshter D, Levartovsky D, Mendelson E, Wigler I, Caspi D, Paran D.

Semin Arthritis Rheum. 2010 Jun;39(6):442-7. doi: 10.1016/j.semarthrit.2008.12.002. Epub 2009 Feb 26.

PMID:
19246078
16.

Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.

Schabert VF, Watson C, Joseph GJ, Iversen P, Burudpakdee C, Harrison DJ.

J Manag Care Pharm. 2013 Oct;19(8):621-30.

17.

RF positivity has substantial influence on the peripheral memory B-cell compartment and its modulation by TNF inhibition.

Roll P, Muhammad K, Schumann M, Kleinert S, Tony HP.

Scand J Rheumatol. 2012 May;41(3):180-5. doi: 10.3109/03009742.2011.645056. Epub 2012 Mar 9.

PMID:
22400711
18.

Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?

Askling J, van Vollenhoven RF, Granath F, Raaschou P, Fored CM, Baecklund E, Dackhammar C, Feltelius N, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Rantapää-Dahlqvist S, Saxne T, Klareskog L.

Arthritis Rheum. 2009 Nov;60(11):3180-9. doi: 10.1002/art.24941.

19.

Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis.

Kapetanovic MC, Saxne T, Sjöholm A, Truedsson L, Jönsson G, Geborek P.

Rheumatology (Oxford). 2006 Jan;45(1):106-11. Epub 2005 Nov 15.

PMID:
16287919
20.

Use of a disease risk score to compare serious infections associated with anti-tumor necrosis factor therapy among high- versus lower-risk rheumatoid arthritis patients.

Curtis JR, Xie F, Chen L, Muntner P, Grijalva CG, Spettell C, Fernandes J, McMahan RM, Baddley JW, Saag KG, Beukelman T, Delzell E.

Arthritis Care Res (Hoboken). 2012 Oct;64(10):1480-9. doi: 10.1002/acr.21805.

Supplemental Content

Support Center